Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms CN 201, CN201 |
Target |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD3 inhibitors(T cell surface glycoprotein CD3 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pre B-cell acute lymphoblastic leukemia | Phase 2 | CN | 01 Nov 2022 | |
B-cell lymphoma recurrent | Phase 1 | CN | 16 Mar 2021 | |
B-cell lymphoma refractory | Phase 1 | CN | 16 Mar 2021 | |
B-Cell Lymphoma | Phase 1 | CN | 04 Mar 2021 | |
B-Cell Leukemia | IND Approval | CN | 09 Nov 2020 |
Phase 1 | Refractory B Acute Lymphoblastic Leukemia Philadelphia chromosome-positive | 42 | xztgnkogpv(iazkyjkona) = MRD negativity (75%) kjfbxucmym (vuyzszvvwo ) View more | Positive | 24 May 2024 | ||
Phase 1 | 58 | xemcoolewb(hnbypbwmda) = 7% objjyaeqew (edhrfbhyjn ) View more | Positive | 24 May 2024 |